Treatment of Hepatitis C Virus with Direct Acting Antivirals (DAA) and Ribavirin (RBV) is Associated with Changes in Serum Apolipoprotein and TNF-alpha Levels

被引：0
|
作者：
Golabi, Pegah [2 ]
Sayiner, Mehmet [2 ]
Estep, Michael J. [2 ]
Elsheikh, Elzafir [2 ]
Lam, Brian P. [2 ]
Pham, Huong T. [2 ]
Stepanova, Maria [2 ]
Younossi, Zobair M. [1 ,2 ]
机构：
[1] Inova Fairfax Hosp, Dept Med, Ctr Liver Dis, Falls Church, VA USA
[2] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1186
引用
收藏
页码：796A / 796A
页数：1
相关论文
共 50 条
  • [1] Ribavirin in the New Era of Direct-acting Antivirals (DAA) for Hepatitis C Virus (HCV): How Low Is Low Dose Ribavirin?
    Dutta, Sangitanjan
    Talukdar, Anjan Jyoti
    Tiwari, Avinash
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1496 - S1497
  • [2] Is There a Role for Ribavirin in the Era of Hepatitis C Virus Direct-Acting Antivirals?
    Feld, Jordan J.
    GASTROENTEROLOGY, 2012, 142 (06) : 1356 - 1359
  • [3] ELEVATED SERUM LEVELS OF TNF-ALPHA IN PATIENTS WITH DIASTOLIC DYSFUNCTION AND HEPATITIS C VIRUS INFECTION
    Che Wenliang
    Hu Dayi
    HEART, 2013, 99 : E279 - E279
  • [4] IMPACT OF HEPATITIS C VIRUS (HCV) ERADICATION FOLLOWING DIRECT ACTING ANTIVIRALS TREATMENT (DAA) ON LIVER STIFFNESS MEASUREMENT (LSM)
    Khalil, Mohammed Tag-Adeen S.
    Sapra, Ahlam M.
    Akazawa, Yuko
    Ohnita, Ken
    Nakao, Kazuhiko
    GASTROENTEROLOGY, 2017, 152 (05) : S1105 - S1106
  • [5] Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome
    Ball, Lauren E.
    Agana, Bernice
    Comte-Walters, Susana
    Rockey, Don C.
    Masur, Henry
    Kottilil, Shyam
    Meissner, Eric G.
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (11) : 1614 - 1623
  • [6] GLOMERULAR FILTRATION RATES AND NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN DURING TREATMENT WITH DIRECT ACTING ANTIVIRALS (DAA) FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
    Coppolino, Giuseppe
    Strazzulla, Alessio
    Barreca, Giorgio
    Gentile, Innocenza
    Rivoli, Laura
    Postorino, Maria Concetta
    Mazzitelli, Maria
    Greco, Giuseppe
    Costa, Chiara
    Pisani, Vincenzo
    Marascio, Nadia
    Simeoni, Maria Adelina
    Foca, Alfredo
    Foti, Daniela
    Gulletta, Elio
    Fuiano, Giorgio
    Torti, Carlo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [7] Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels
    Younossi, Z. M.
    Elsheikh, E.
    Stepanova, M.
    Gerber, L.
    Nader, F.
    Stamm, L. M.
    Brainard, D. M.
    McHutchinson, J. G.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (12) : 977 - 982
  • [8] MINIMAL IMPORTANT DIFFERENCE (MID) OF RESPONSE TO THE HEPATITIS-C VIRUS PATIENT REPORTED OUTCOMES (HCV-PRO) INSTRUMENT IN A TRIAL OF PEGYLATED INTERFERON/RIBAVIRIN (PEGIFN/RBV) AND DIRECT-ACTING-ANTIVIRALS (DAA)
    Baran, R. W.
    Anderson, R. T.
    Dietz, B.
    Gooch, K.
    VALUE IN HEALTH, 2013, 16 (07) : A362 - A363
  • [9] Natural History of Decompensated Cirrhosis after Direct-Acting Antivirals (DAA) Treatment of Hepatitis C (HCV)
    Dunn, Winston
    Whitener, Melissa
    Chakraborty, Shweta
    Vittal, Anusha
    Pandya, Prashant K.
    Kallail, K. James
    Bridges, Brian
    Wu, Chuanghong
    Taylor, Ryan
    Olson, Jody C.
    Gilroy, Richard
    Schmitt, Timothy
    Olyaee, Mojtaba S.
    Weinman, Steven A.
    HEPATOLOGY, 2015, 62 : 1093A - 1094A
  • [10] The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of Chronic Hepatitis C
    Gaetano, John N.
    Desai, Archita P.
    Reau, Nancy
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2012, 4 : 39 - 56
12345